Publisher's Synopsis
Suitable for those wishing to better understand the issues surrounding the use of Health Technology Assessments (HTAs) and similar mechanisms in the assessment of rare disease therapies, this title provides an overview of the challenges faced, outlining the viewpoints of key expert stakeholders in the field.